Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2002

View Archived Issues

Devgen enters into target validation collaboration with Genentech

Celexa's marketing exclusivity extended by six months

Xyrem approved for cataplexy associated with narcolepsy

Advicor marketing application submitted in Europe

Genome to advance two lead compound series from ArQule collaboration into optimization

Deltagen discovers drug target with potential in rheumatoid arthritis

First radiolabeled probe for imidazoline I1 receptors

NO-donating, selective COX-2 inhibitor with beneficial cardiovascular profile

Novel thymulin-related peptide with antihyperalgesic/analgesic effects in rat models

Flupirtine improves cognition in Creutzfeldt-Jakob disease patients

Multiple neuroprotective actions described for dehydroevodiamine in Stockholm

Early clinical results discussed for lipid A antagonist at IUPHAR 2002

New Tie-2 and/or VEGFR-2 inhibitors and their use in cancer

Pfizer identifies carbazole NPY Y5 antagonists

Yamanouchi presents novel apo B secretion inhibitors for lipoprotein disorders

Cyclophilin ligands with neurotrophic activity reported by Guilford

Selective PARP1/PARP2 inhibitors described by Iconix R&D team

A new carrageenan-based microbicide gel for sexually transmitted diseases

New lanosterol synthase inhibitors under study at Roche

Synthesis and use of dopamine D3 antagonists as antipsychotics described in recent patent

SomatoKine granted orphan drug status in GH insensitivity syndrome

PD-166793 inhibition of MMP attenuates volume overload-induced myocardial remodeling

Phase IIa results of DX-890 in cystic fibrosis

TAK-456 shows potential in the treatment of candidiasis and aspergillosis

Phase II Aroplatin trial enrolling in metastatic colorectal cancer

FDA committee recommends Atacand superiority claim on label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...